Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Trispecific antibody targeting CD79b, CD20, and CD3

Trispecific antibody targeting CD79b, CD20, and CD3

US Patent 12103977 · Granted Oct 1, 2024

Estimated economic value: $601,237,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Materials and methods for producing bioengineered virus specific lymphocytes2025
Methods and compositions for modulating beta chain mediated immunity2025
Gas turbine engine fuel nozzle having a secondary fuel passage through a swirler2025
Mixer vanes2025
Combustor for a gas turbine engine2025
Proteins comprising CD3 antigen binding domains and uses thereof2025
Immune targeting molecules and uses thereof2025
Anti-Vβ17/anti-CD123 bispecific antibodies2025
Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin sin2025
Antibody targeting CD22 and CD79B2024
Antibody targeting CD22 and CD79B2024
Antibody targeting CD22 and CD79B2024